



STATE MEDICAID P&T COMMITTEE MEETING
 THURSDAY, March 21, 2012
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 128



MINUTES

Committee Members Present:

Kort Delost, R.Ph.

Lisa Hunt, R.Ph.

Roger Martenau, M.D.

Beth Johnson, R.Ph.

Bernadette Kiraly, M.D.

Julia Ozbolt, M.D.

Jameson Rice, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D.

Richard Sorenson, R.N.

Trevor Smith, CPhT

Bobbi Hansen, CPhT.

Tim Morley, R.Ph.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Kathleen Somera-Molina, Acorda Therapeutics

Joanita Lake, UofU

Greg Rechtenbach, Aptalis

Scott Larson, BMS

Julie Porter, Novartis

Barbara Boner, Novartis

Craig Black, Biogen

Brad Buysthe, Elan

Wayne Roberts, GSK

Debora Progant, Teva

Tom Holder, Aptalis

Pat Wisend, Med

Paul Bonher, NovoNordisk

Mark Germann, Novartis

Evan Riddle, Biogen

Mike Broadhead, Abbvik

Dana Dewitt, UofU

Brooks Hubbard, BIPP

Meeting conducted by: Lisa Hunt.

- 1 Review and Approval of December Minutes: Beth Johnson made a motion to approve the minutes. Kort Delost seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt reported a new PDL will be released dated April 1st. There will be seven new classes included with the change.
- 3 Drug Utilization Review (DUR) Board update: Robyn Seely reported that for the March meeting, they had the required yearly Open Meeting Act training, and discussed DPP4 drugs. Next month's DUR topic is overactive bladder medications.

4 **Multiple Sclerosis Agents Update** – Melissa Archer provided a clinical overview of March 2013

each of the MS agents being discussed (Gilenya and Aubagio). Based off clinical safety and efficacy the recommendations of the University of Utah College of Pharmacy recommend to include (as preferred on PDL) at least one oral or injectable disease modifying agent.

Lisa Hunt reported how the other states in the Sovereign States Drug Consortium are currently covering MS agents.

Public Comment:

- Deborah Profant, Ph.D, Medical Science Liaison, Teva. She discussed Copaxone and information related to this drug.
- Julie Porter, PharmD, Novartis. Discussed Gilenya and information related to this drug. First line status, oral formulation can result in better results than injectable alternatives.
 - Standard dispensing available in only specialty pharmacies, rare exceptions
 - Questions and comments from Bernadette Kiraly, Beth Johnson, Lisa Hunt, Jamison Rice.
 - Information about local drug distribution from Mark Germann, Novartis.
- Dana DeWitt, Physician UofU. She currently treats patients diagnosed with MS. She gave support for an oral form of a MS drug. She said she usually starts patients on a first line injectable form, and will switch to or use the oral form if patient prefers it, or is not compliant with injectable forms.
 - Questions from Bernadette Kiraly, Roger Martenau and Julie Ozbolt concerning percentage of patients who Ms. DeWitt uses injectable vs oral form.
- Evan Riddle, PharmD, Biogen Idec. Discussed Avonex and and information related to this drug.
- Kathleen Somera-Molina, PhD, Acodra Therapeutics. Discussed Ampyra and information related to this drug.

5 Board Actions: The committee discussed and voiced concerns about making a determination on the use of a new drug where safety issues are associated with it. Bernadette Kiraly made the motion that the two oral agents do not appear to equally safe. The newer agent Aubagio is not equally safe and effective as the more established Gilenya. Kort Delost seconded the motion. Beth Johnson abstained from the vote. The motion was approved unanimously.

Beth Johnson made a motion to include an oral agent to treat MS on the PDL. The original motion was seconded by Bernadette Kiraly. During discussion, Lisa Hunt said for the record that using an injectable form first and then using a Prior Authorization to switch to the oral form upon failure or non-compliance is acceptable. The original motion was approved unanimously.

Next Meeting Set for Thursday, April 18, 2013 – Sulfonylurea Drug Class review,
and Committee chair elections
Meeting Adjourned.
Minutes prepared by Trevor Smith.